Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature

Research and Reports in Urology, Journal Year: 2025, Volume and Issue: Volume 17, P. 69 - 85

Published: March 1, 2025

Bladder cancer management, particularly non-muscle-invasive bladder (NMIBC), has evolved significantly due to advancements in imaging techniques and surgical methodologies. Enhanced tumor visualization methods, including Photodynamic Diagnosis (PDD) Narrow-Band Imaging (NBI), offer improved detection rates for both papillary tumors carcinoma situ (CIS), compared traditional white-light cystoscopy (WLC). Recent studies suggest that these technologies enhance diagnostic accuracy, reduce recurrence rates, improve oncological outcomes. Additionally, transurethral resection of (TURBT), performed with advanced imaging, demonstrated better quality, terms detrusor muscle presence. Despite innovations, challenges remain the long-term impact on recurrence-free progression-free survival. Artificial intelligence (AI) integration into cystoscopic further promises enhanced precision cost-effective management. As personalized treatment paradigms emerge, predictive biomarkers, genomic pathological markers, may help stratify patients aggressive treatment, sparing those at lower risk from unnecessary interventions. Future research should focus validating AI models combining them modalities refine protocols further. These collectively represent a significant leap toward medicine care.

Language: Английский

French AFU Cancer Committee Guidelines – Update 2024–2026: Non-muscle invasive bladder cancer (NMIBC)

Deleted Journal, Journal Year: 2024, Volume and Issue: 34(12), P. 102742 - 102742

Published: Nov. 1, 2024

To update the CCAFU recommendations for management of non-muscle invasive bladder cancer (NMIBC). A systematic review (Medline) literature from 20222024 was performed, taking into account elements diagnosis, treatment options and monitoring NMIBC evaluating references with their level evidence. The diagnosis (Ta, T1, or CIS) is made after complete deep tumour resection. use photodynamic indication a second TURBT (4 to 6weeks later) help improve initial diagnosis. risk recurrence and/or progression assessed via EORTC score. By stratifying patients low-, intermediate- high-risk groups, adjuvant can be proposed, including endovesical instillations chemotherapy (immediate postoperative regimen), BCG (induction maintenance even cystectomy unresponsive patients. Updating CCAFU's should patient management, as well NMIBC.

Language: Английский

Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2024–2026 : tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)

Progrès en Urologie - FMC, Journal Year: 2024, Volume and Issue: 34(7), P. F272 - F295

Published: Nov. 1, 2024